yeztugo gilead sciences

News

FDA, HIV and Gilead Sciences

Gilead Sciences CEO on FDA approval of Yeztugo: A milestone moment in the history of HIV

Gilead Sciences chairman and CEO Daniel O’Day joins 'Squawk Box' to discuss the FDA approval of the company's HIV prevention medication, how the twice-yearly antiviral drug Yeztugo works, the importance of preventive medicine,

The Jerusalem Post on MSN · 2d

FDA approves Yeztugo: Gilead's new twice-yearly HIV prevention injection

He affirmed that the new drug "could take the epidemic to the history books," according to Mother Jones.Yeztugo, based on the molecule lenacapavir, offers a more effective and less invasive prevention method,

Yahoo Finance · 3d

Gilead Sciences (NasdaqGS:GILD) Gains FDA Approval For Yeztugo As PrEP HIV Option

Gilead Sciences (NasdaqGS:GILD) recently achieved FDA approval for Yeztugo, a significant step in HIV prevention as the first twice-yearly PrEP option in the U.S., supported by strong Phase 3 data. Although the company reported a return to profitability in its latest earnings,

2don MSN

Here’s what everyone should know about this new HIV prevention shot

Yeztugo, approved by the FDA, was highly effective in two randomized trials. It costs $28,218 per year, and people have to be ...

MedCity News4d

Gilead Sciences Lands First FDA Approval of a Twice-a-Year HIV PrEP Drug

A Gilead Sciences drug that protects against HIV infection ... For this indication, Gilead will market the drug under the brand name Yeztugo. Gilead has experience with PrEP drugs.

4don MSN

The world’s only twice-a-year shot to prevent HIV could stop transmission — if people can get it

The Food and Drug Administration has approved the world’s only twice-a-year shot to prevent HIV. In two groundbreaking ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results